Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Other Accumulated Expenses: 2019-2022

Historic Other Accumulated Expenses for C4 Therapeutics (CCCC) over the last 1 years, with Mar 2022 value amounting to $309,000.

  • C4 Therapeutics' Other Accumulated Expenses fell 65.16% to $309,000 in Q1 2022 from the same period last year, while for Mar 2022 it was $309,000, marking a year-over-year decrease of 65.16%. This contributed to the annual value of $413,000 for FY2021, which is 11.94% down from last year.
  • Per C4 Therapeutics' latest filing, its Other Accumulated Expenses stood at $309,000 for Q1 2022, which was down 25.18% from $413,000 recorded in Q4 2021.
  • In the past 5 years, C4 Therapeutics' Other Accumulated Expenses ranged from a high of $887,000 in Q1 2021 and a low of $164,000 during Q3 2020.
  • In the last 3 years, C4 Therapeutics' Other Accumulated Expenses had a median value of $309,000 in 2022 and averaged $383,714.
  • Per our database at Business Quant, C4 Therapeutics' Other Accumulated Expenses skyrocketed by 67.50% in 2020 and then plummeted by 65.16% in 2022.
  • Over the past 4 years, C4 Therapeutics' Other Accumulated Expenses (Quarterly) stood at $280,000 in 2019, then soared by 67.50% to $469,000 in 2020, then decreased by 11.94% to $413,000 in 2021, then tumbled by 65.16% to $309,000 in 2022.
  • Its Other Accumulated Expenses stands at $309,000 for Q1 2022, versus $413,000 for Q4 2021 and $201,000 for Q3 2021.